Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Notebook: Industry’s Post-EU Election Goals; IMI2 Gets Under Way; FDA/EMA Tie-Up On Childhood Gaucher Studies

Executive Summary

Worries about science bases drew European politicians to the AstraZeneca/Pfizer merger debate; the European industry calls for EU-wide R&D agenda, standards of care; IMI2 public-private partnership gets under way; FDA and EMA to collaborate on clinical trials for childhood Gaucher disease.

Advertisement

Related Content

Pfizer Uses Layered Knowledge Management To Guide Tech Transfers
EFPIA Urges Drug Makers To See Value In Mobile Apps
Firms May Lose Data Exclusivity Earlier Under Planned EU Adaptive Licensing Regime
U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs
M&A Activity Up Year-Over-Year, Driven By Tax-Inversion Deals And Diversification

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel